Secondary treatment of polycythemia rubra vera with 6-thioguanine

Focal segmental glomerulosclerosis in a patient with polycythemia rubra vera.

Treatment of polycythemia vera.

BACKGROUND AND OBJECTIVE Current guidelines for the management of patients with polycythemia vera (PV) derive from a few clinical trials and several uncontrolled clinical studies. The purpose of this paper is to critically review the available evidence in literature for selecting the best treatment in the single patient. METHODS The authors have been working in this field contributing origina...

Erythropoietic activity in the plasma of patients with polycythemia vera and secondary polycythemia.

\IIRIAM E. SIMPSON P OIAYCYTHI’\IIA VERA is a consditions which is still nsot well unsderst.ood. It has beens shown that. the increase ins the total volunuse of red cells ins this (Ofl(litiOts iS due prinuarily to ais inscreased rat-c of red cell product-ion and not. to an increase ins the life spats of the red cells.m Previously, sic have reported the presenice of ats erythropoietic factor cir...

Polycythemia rubra vera with pernicious anemia. Some observations on vitamin B 12 metabolism.

By ROBERT E. SAGE P ERSISTENT rather than relative and transient polycythemia was first described in 1892 by Vaquez.’ Polycythemia rubra vera is now regarded as one of the myeloproliferative disorders. A slowly progressive neoplasm of unknown etiology involving all cell series of the bone marrow, it is inevitably fatal after a varying period of time.24 The first clinical description of pernicio...

Ruxolitinib for the treatment of patients with polycythemia vera.

Polycythemia vera (PV) is a hematopoietic proliferative disorder associated with Janus-associated kinase/signal transducer and activator of transcription pathway dysregulation resulting in erythrocytosis and, possibly, leukocytosis and thrombocytosis. Patients diagnosed with PV experience a broad range of symptoms associated with a reduced quality of life, often develop splenomegaly, and have a...